EP4281452A4 - Modulatoren von fpr1 und verfahren zu ihrer verwendung - Google Patents

Modulatoren von fpr1 und verfahren zu ihrer verwendung Download PDF

Info

Publication number
EP4281452A4
EP4281452A4 EP21920261.1A EP21920261A EP4281452A4 EP 4281452 A4 EP4281452 A4 EP 4281452A4 EP 21920261 A EP21920261 A EP 21920261A EP 4281452 A4 EP4281452 A4 EP 4281452A4
Authority
EP
European Patent Office
Prior art keywords
fpr1
modulators
methods
fpr1 modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21920261.1A
Other languages
English (en)
French (fr)
Other versions
EP4281452A1 (de
Inventor
Fu-Dong Shi
Yongjun Wang
Qiang Liu
Zhiguo Li
Tianwei Ma
Zheng Huang
Feng Shi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biofront Therapeutics Beijing Co Ltd
Beijing Tiantan Hospital
Original Assignee
Biofront Therapeutics Beijing Co Ltd
Beijing Tiantan Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofront Therapeutics Beijing Co Ltd, Beijing Tiantan Hospital filed Critical Biofront Therapeutics Beijing Co Ltd
Publication of EP4281452A1 publication Critical patent/EP4281452A1/de
Publication of EP4281452A4 publication Critical patent/EP4281452A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP21920261.1A 2021-01-21 2021-01-21 Modulatoren von fpr1 und verfahren zu ihrer verwendung Pending EP4281452A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2021/073154 WO2022155859A1 (en) 2021-01-21 2021-01-21 Modulators of fpr1 and methods of using the same

Publications (2)

Publication Number Publication Date
EP4281452A1 EP4281452A1 (de) 2023-11-29
EP4281452A4 true EP4281452A4 (de) 2024-11-06

Family

ID=82548296

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21920261.1A Pending EP4281452A4 (de) 2021-01-21 2021-01-21 Modulatoren von fpr1 und verfahren zu ihrer verwendung

Country Status (5)

Country Link
US (1) US20240109897A1 (de)
EP (1) EP4281452A4 (de)
JP (1) JP7830488B2 (de)
CN (1) CN117157296A (de)
WO (1) WO2022155859A1 (de)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008120725A1 (ja) * 2007-03-30 2008-10-09 Shionogi & Co., Ltd. 新規ピロリノン誘導体およびそれを含有する医薬組成物
WO2016189876A1 (en) * 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201016880D0 (en) * 2010-10-07 2010-11-17 Riotech Pharmaceuticals Ltd Phosphodiesterase inhibitors
JP5992054B2 (ja) * 2011-11-29 2016-09-14 ノバルティス アーゲー ピラゾロピロリジン化合物
US8975417B2 (en) * 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
EP3634958B1 (de) * 2017-06-09 2021-07-21 Bristol-Myers Squibb Company Cyclopropyl-harnstoff-formylpeptid-2-rezeptor- und formylpeptid-1-rezeptor-agonisten
KR102803660B1 (ko) * 2018-03-05 2025-05-02 브리스톨-마이어스 스큅 컴퍼니 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제
CN113166134B (zh) * 2018-11-26 2024-06-14 百时美施贵宝公司 作为甲酰肽2受体激动剂的吡咯烷酮衍生物
CN111406752B (zh) * 2020-04-23 2021-07-23 中国农业科学院植物保护研究所 二氢吡咯并吡唑酮类衍生物作为几丁质酶抑制剂或杀线虫剂的应用
WO2022155860A1 (en) * 2021-01-21 2022-07-28 Biofront Therapeutics (Beijing) Co., Ltd. Modulators of fpr1 and methods of using the same
WO2022193187A1 (en) * 2021-03-17 2022-09-22 Biofront Ltd. (Cayman) Modulators of fpr1 and methods of using same
CN115317611B (zh) * 2022-07-05 2023-07-28 天津天海新域生物科技有限公司 Fpr1拮抗剂t-0080在制备用于治疗动脉粥样硬化症药物中的应用
WO2025118148A1 (en) * 2023-12-05 2025-06-12 Biofront Ltd Antioxidant drug-conjugate modulators of fpr1, compositions comprising the modulator, and methods of using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008120725A1 (ja) * 2007-03-30 2008-10-09 Shionogi & Co., Ltd. 新規ピロリノン誘導体およびそれを含有する医薬組成物
WO2016189876A1 (en) * 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GARCIA GEORGE A ET AL: "Novel Chemical Scaffolds for Inhibition of Rifamycin-Resistant RNA Polymerase Discovered from High-Throughput Screening", BIOORG.&MED. CHEM., vol. 26, 1 January 2017 (2017-01-01), pages 290 - 297, XP093205854, DOI: 10.1177/2472555216679994 *
See also references of WO2022155859A1 *
ZHOU DONGHUI ET AL: "Small molecules inhibitex vivotumor growth in bone", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 26, no. 23, 2018, pages 6128 - 6134, XP085548897, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2018.11.025 *

Also Published As

Publication number Publication date
WO2022155859A1 (en) 2022-07-28
JP2024507672A (ja) 2024-02-21
CN117157296A (zh) 2023-12-01
JP7830488B2 (ja) 2026-03-16
EP4281452A1 (de) 2023-11-29
US20240109897A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
MA55890A (fr) Modulateurs de thr-beta et leurs procédés d'utilisation
EP4236990A4 (de) Interleukin-18-varianten und verfahren zur verwendung
MA56457A (fr) Modulateurs de hsd17b13 et leurs procédés d'utilisation
MA52390A (fr) Anticorps anti-coronavirus et procédés d'utilisation
MA56074A (fr) Anticorps contre le sars-cov-2 et leurs procédés d'utilisation
EP3911648A4 (de) Pcsk9-inhibitoren und verfahren zur verwendung davon
EP3911640A4 (de) Pcsk9-inhibitoren und verfahren zur verwendung davon
MA55025A (fr) Anticorps anti-trem2 et leurs procédés d'utilisation
EP4329521A4 (de) Kollagenzusammensetzungen und verfahren zur verwendung davon
EP4125831A4 (de) Kcnt1-inhibitoren und verfahren zur verwendung
EP4284365A4 (de) Cdk2-inhibitoren und verfahren zur verwendung davon
MA51837A (fr) Inhibiteurs de l'arginase et leurs procédés d'utilisation
EP4319813A4 (de) Peptid-mhc-immunglobulinmultimere und verfahren zur verwendung davon
EP4161967A4 (de) Auf b7h3 abzielende proteine und verfahren zur verwendung davon
EP3909063A4 (de) Multiplex-assay und verfahren zur verwendung davon
EP4423205A4 (de) Polierzusammensetzungen und verfahren zur verwendung davon
EP4211233A4 (de) Zusammensetzungen und verfahren zur verwendung davon
EP4168541A4 (de) Ace2-muteine und verfahren zur verwendung davon
EP4175624A4 (de) Kcnt1-inhibitoren und verfahren zur verwendung
EP3938400A4 (de) Cd22-antikörper und verfahren zur verwendung davon
EP3806834A4 (de) Dynamische klemmen und verwendungsverfahren dafür
EP4136220A4 (de) Cannabinoidsynthasevarianten und verfahren zu deren verwendung
EP4267133A4 (de) Kcnt1-inhibitoren und verfahren zur verwendung
EP3987030A4 (de) Ppm1a-inhibitoren und verfahren zur verwendung davon
EP3965776A4 (de) Oligosaccharidzusammensetzungen und verfahren zur verwendung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230704

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40101030

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20241007

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/00 20060101ALI20240930BHEP

Ipc: A61K 31/424 20060101ALI20240930BHEP

Ipc: A61K 31/4162 20060101ALI20240930BHEP

Ipc: C07D 487/04 20060101AFI20240930BHEP